Cencora, Inc. $COR Shares Sold by First Trust Advisors LP

First Trust Advisors LP reduced its position in shares of Cencora, Inc. (NYSE:COR) by 15.9% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 734,192 shares of the company’s stock after selling 138,505 shares during the quarter. First Trust Advisors LP owned about 0.38% of Cencora worth $220,147,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares during the period. Costello Asset Management INC bought a new stake in Cencora in the first quarter worth about $28,000. Vermillion & White Wealth Management Group LLC lifted its holdings in Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after acquiring an additional 43 shares during the last quarter. Twin Peaks Wealth Advisors LLC bought a new position in shares of Cencora during the 2nd quarter valued at about $52,000. Finally, Hantz Financial Services Inc. boosted its position in shares of Cencora by 712.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 203 shares of the company’s stock valued at $61,000 after purchasing an additional 178 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on COR shares. Evercore ISI set a $400.00 target price on shares of Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. JPMorgan Chase & Co. increased their price objective on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Robert W. Baird raised their price objective on Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, Wells Fargo & Company boosted their target price on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $371.09.

Cencora Stock Up 0.6%

COR opened at $337.43 on Friday. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The company has a market capitalization of $65.42 billion, a PE ratio of 42.44, a price-to-earnings-growth ratio of 1.59 and a beta of 0.63. The business has a 50-day moving average of $339.40 and a 200-day moving average of $309.16. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $377.54.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. The company had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio is 30.19%.

Insiders Place Their Bets

In related news, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 46,640 shares of company stock worth $14,099,338 over the last quarter. 10.80% of the stock is currently owned by company insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.